SORBITAN SESQUIOLEATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	3C18H34O2.2C6H14O6
Molecular Weight	1211.7276
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	3
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O

InChI

InChIKey=CUNWUEBNSZSNRX-RKGWDQTMSA-N

InChI=1S/3C18H34O2.2C6H14O6/c3*1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20;2*7-1-3(9)5(11)6(12)4(10)2-8/h3*9-10H,2-8,11-17H2,1H3,(H,19,20);2*3-12H,1-2H2/b3*10-9-;;/t;;;2*3-,4+,5-,6-/m...11/s1

HIDE SMILES / InChI

Molecular Formula	C6H14O6
Molecular Weight	182.1718
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C18H34O2
Molecular Weight	282.4614
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: http://www.webmd.com/drugs/2/drug-64292/sorbitan-sesquioleate-topical/details | https://www.truthinaging.com/ingredients/sorbitan-sesquioleate

A sorbitol derivative emulsifier used in many topical agents. Sorbitan Sesquioleate is used in a variety of products including skin care products, skin cleansing products, moisturizers, eye makeup and other makeup, primarily as an emollient. It is added to formulas as a skin soother and moisturizer and is derived from sorbitol, a humectant. Sorbitol sesquioleate (SSO) have recently been implicated in allergic dermatitis.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Dermatoses 23 Sources: http://www.webmd.com/drugs/2/drug-64292/sorbitan-sesquioleate-topical/details	Inactive ingredient		Approved 8583	Clobetasol propionate ointment Approved Use Clobetasol propionate cream and ointment are super-high potency corticosteroid formulations indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Use in children under 12 years of age is not recommended. Launch Date 1996

PubMed

Title	Date	PubMed
Allergic contact dermatitis caused by sorbitan sesquioleate imitating severe glove dermatitis in a patient with filaggrin mutation.	2013-11	24117742
Contact allergy to sorbitans: a follow-up study.	2012-07-26	22828254
Drug distribution in enteric microparticles.	2009-09-08	19505543
The robustness and flexibility of an emulsion solvent evaporation method to prepare pH-responsive microparticles.	2009-07-30	19515519
Fabrication and in vivo evaluation of highly pH-responsive acrylic microparticles for targeted gastrointestinal delivery.	2009-06-28	19491017

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Wed Apr 02 18:22:45 GMT 2025` Edited by `admin` on `Wed Apr 02 18:22:45 GMT 2025`
Record UNII	0W8RRI5W5A
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SORBITAN SESQUIOLEATE [VANDF]

Preferred Name

English

SORBITAN SESQUIOLEATE

Official Name

English

SORBITAN SESQUIOLEATE [USAN]

Common Name

English

SORBITAN SESQUIOLEATE [EP MONOGRAPH]

Common Name

English

SORBITAN SESQUIOLEATE [MART.]

Common Name

English

SORBITAN SESQUIOLEATE [II]

Common Name

English

SORBITAN SESQUIOLEATE [JAN]

Common Name

English

SORBITAN SESQUIOLEATE [EP IMPURITY]

Common Name

English

Sorbitan sesquioleate [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C83486